Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus TACE in unresectable advanced liver cancer (real-world study)
ChiCTR2000040303Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Efficacy and Safety. Started Nov 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2000040303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040303.